Literature DB >> 2932585

Effects of intraperitoneal administration of OK-432 for patients with advanced cancer.

T Toge, H Yamada, K Aratani, A Kameda, K Kuroi, K Hisamatsu, T Hattori.   

Abstract

The effects of intraperitoneal administration of OK-432 on tumor cells in ascites, in relation to the infiltration of effector cells and on the immune responses of the host, particularly, with regard to immune suppressive mechanisms, were investigated in 25 patients with cancerous ascites. The effects of OK-432 depended on frequency of the repeated and continuous administrations through a tube placed in the peritoneum during laparotomy. Infiltrations of neutrophils and lymphocytes were observed in the ascites within a short period after the administration and monocyte infiltration followed. Disappearance of tumor cells correlated well with the infiltration of these cells. No marked changes in the proliferative responses of peripheral blood lymphocytes were noted and decreases in serum inhibitory factor levels in sera were observed in patients given larger doses of OK-432. A marked reduction in Concanavalin-A-induced suppressor cell activities was observed after OK-432 administration. OK-432 administration probably leads to a disappearance of tumor cells by enhancing peritoneal effector cell activities and by inhibiting the induction of suppressor cell activities, in a dose dependent manner.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932585     DOI: 10.1007/BF02469915

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  14 in total

1.  Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancer.

Authors:  T Toge; H Ikeda; N Senoo; M Niimoto; T Hattori
Journal:  Jpn J Surg       Date:  1976-12

2.  Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432.

Authors:  Y Ishii; H Yamaoka; K Toh; K Kikuchi
Journal:  Gan       Date:  1976-02

3.  Lymphocyte responsiveness to phytohemagglutinin and its modification by serum inhibitor in breast cancer patients.

Authors:  T Toge; Y Nagusa; A Nakano; H Ikeda; T Hattori
Journal:  Gan       Date:  1979-04

4.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.

Authors:  M Torisu; M Katano; Y Kimura; H Itoh; M Takesue
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

5.  Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432.

Authors:  Y Watanabe; T Iwa
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

6.  Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro.

Authors:  A Uchida; T Hoshino
Journal:  Cancer       Date:  1980-02       Impact factor: 6.860

7.  Concanavalin A-induced and spontaneous suppressor cell activities in peripheral blood lymphocytes and spleen cells from gastric cancer patients.

Authors:  T Toge; S Hamamoto; E Itagaki; K Yajima; M Tanada; H Nakane; H Kohno; K Nakanishi; T Hattori
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

8.  Cellular suppression of murine ADCC and NK activities induced by Corynebacterium parvum.

Authors:  V K Milisauskas; G Cudkowicz; I Nakamura
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells.

Authors:  A Uchida; M Micksche
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

10.  Concanavalin A-activated suppressor cell activity in gastric cancer patients.

Authors:  T Toge; E Yanagawa; K Nakanishi; Y Yamada; M Niimoto; T Hattori
Journal:  Gan       Date:  1980-12
View more
  3 in total

1.  The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials.

Authors:  Mari S Oba; Satoshi Teramukai; Yasuo Ohashi; Kenji Ogawa; Yoshihiko Maehara; Junichi Sakamoto
Journal:  Gastric Cancer       Date:  2015-03-25       Impact factor: 7.370

2.  The clinical efficacy of intratumoral OK-432 administration in advanced cancer patients.

Authors:  T Toge; H Kuninobu; Y Yamaguchi; N Baba; Y Kegoya; T Hattori
Journal:  Jpn J Surg       Date:  1988-11

3.  Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study.

Authors:  K Sugimachi; Y Maehara; K Akazawa; Y Kondo; Y Kunii; M Kitamura; H Yamaoka; Y Takahashi; T Kito; M Katou
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.